These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 33339986)

  • 1. Rheumatic disease and COVID-19: epidemiology and outcomes.
    Hyrich KL; Machado PM
    Nat Rev Rheumatol; 2021 Feb; 17(2):71-72. PubMed ID: 33339986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 in Rheumatic Diseases: A Research Agenda.
    Yazdany J
    Arthritis Rheumatol; 2020 Oct; 72(10):1596-1599. PubMed ID: 32705748
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.
    Cook C; Patel NJ; D'Silva KM; Hsu TY; DiIorio M; Prisco L; Martin LW; Vanni K; Zaccardelli A; Todd D; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2022 Feb; 81(2):289-291. PubMed ID: 34489304
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques
    D'Silva KM; Serling-Boyd N; Wallwork R; Hsu TY; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2022 Aug; 81(8):e135. PubMed ID: 32660976
    [No Abstract]   [Full Text] [Related]  

  • 5. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
    D'Silva KM; Serling-Boyd N; Hsu TY; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2021 Jun; 80(6):817-819. PubMed ID: 33436385
    [No Abstract]   [Full Text] [Related]  

  • 6. Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy.
    Galarza-Delgado DÁ; Serna-Peña G; Compeán-Villegas JE; Cardenas-de la Garza JA; Pineda-Sic RA; Colunga-Pedraza IJ; Vega-Morales D; Pérez-Barbosa L; Skinner-Taylor CM; Flores-Alvarado DE
    Clin Rheumatol; 2021 Mar; 40(3):1197-1199. PubMed ID: 33231774
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases.
    Celik S; Kutu ME; Bal C; Karadeniz B; Atagunduz P; Soy M
    Clin Exp Rheumatol; 2023 Mar; 41(3):758-759. PubMed ID: 36226619
    [No Abstract]   [Full Text] [Related]  

  • 8. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
    Erre GL; Ferraccioli ES; Piga M; Mangoni A; Passiu G; Gremese E; Ferraccioli G
    Ann Rheum Dis; 2021 Mar; 80(3):e29. PubMed ID: 32424028
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study.
    Francesconi P; Cantini F; Profili F; Mannoni A; Bellini B; Benucci M
    Joint Bone Spine; 2021 May; 88(3):105131. PubMed ID: 33486110
    [No Abstract]   [Full Text] [Related]  

  • 10. Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
    Aydin SZ; Hepworth E; Tugwell P
    Ann Rheum Dis; 2023 Mar; 82(3):e69. PubMed ID: 33355117
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
    Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
    Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
    [No Abstract]   [Full Text] [Related]  

  • 12. Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco
    Giollo A; Bertoldo E; Adami G; Cybulski AJ; Fassio A; Orsolini G; Idolazzi L; Gatti D; Viapiana O; Rossini M
    Ann Rheum Dis; 2022 Nov; 81(11):e222. PubMed ID: 32895237
    [No Abstract]   [Full Text] [Related]  

  • 13. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases.
    Lawson-Tovey S; Hyrich KL; Gossec L; Strangfeld A; Carmona L; Raffeiner B; Yardımcı GK; Trefond L; Roux N; Rodrigues A; Papagoras C; Mateus EF; Mariette X; Machado PM
    Ann Rheum Dis; 2022 Jan; 81(1):145-150. PubMed ID: 34489305
    [No Abstract]   [Full Text] [Related]  

  • 14. [Individual and interdisciplinary treatment of rheumatic diseases in pregnancy].
    Bolz M
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2415. PubMed ID: 18988135
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
    Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
    Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini
    Monti S; Montecucco C
    Ann Rheum Dis; 2021 Feb; 80(2):e15. PubMed ID: 32414805
    [No Abstract]   [Full Text] [Related]  

  • 17. Should we switch from analgesics to the concept of "Pain Modifying Analgesic Drugs (PMADs)" in osteoarthritis and rheumatic chronic pain conditions?
    Perrot S
    Pain; 2009 Dec; 146(3):229-230. PubMed ID: 19695777
    [No Abstract]   [Full Text] [Related]  

  • 18. [A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].
    Schmeiser T; Broll M; Dormann A; Fräbel C; Hermann W; Hudowenz O; Keil F; Müller-Ladner U; Özden F; Pfeiffer U; Saech J; Schwarting A; Stapfer G; Steinchen N; Storck-Müller K; Strunk J; Thiele A; Triantafyllias K; Wassenberg S; Wilden E; Hasseli R
    Z Rheumatol; 2020 May; 79(4):379-384. PubMed ID: 32303821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bibliography. Current world literature. Clinical therapeutics.
    Curr Opin Rheumatol; 2008 May; 20(3):360-6. PubMed ID: 18388531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.